In its endeavor to accelerate the development
process cycle resulting in enhanced “Speed to Market” for its clients, Bilcare
Global Clinical Supplies, a leading single-source provider of Clinical Packaging, Clinical Trial Supplies and services, endorses its continual
capability enhancement commitment by supplementing its ability of developing
functionally viable and innovative formulation dosage forms for pre-clinical
and early-phase drugs.
Vincent Santa Maria, President – Bilcare,
Americas stated that as part of a major capital investment program at its
facilities in the U.S., Bilcare Research has added sophisticated fluid bed
granulation and enhanced capsule filling technologies to its R&D Center.
“With this upgrade, Bilcare Research can now quickly produce a wider variety of
drug dosage forms with high product quality at par industry benchmark. These
investments in R&D services further prove our commitment to being a
full-service partner to our global customers with the offering of a wide breath
of specialty services like clinical packaging, continues Vincent.”
This capability enhancement compliments the
increasing number of investigational new drug (IND) applications by innovator
pharma and Biotech companies, which in turn requires multi-pronged expertise,
more particularly in the Formulation and Analytical research and development,
commented Praful Naik, Ph.D., Chief Scientific Officer, Bilcare Limited.
The fluid-bed granulation technology extends
Bilcare’s solid dosage formulation capabilities. The granulation system
equipped with Wurster coating inserts enables Bilcare to develop and deliver
specialized coating processes for granules and non-pareils with high precision
and consistency for creation of top quality sustained and controlled-release
tablet and capsule formulations.
The In-Cap® capsule system, capable of filling
several thousand capsules per hour in multiple permutations, is a versatile
tool for pre-clinical and early-stage development. This equipment extends both
development and clinical manufacturing capabilities for a myriad of formulation
types including powders, pellets, tablets and liquids.
“Bilcare’s R&D center can now develop a
broad array of dosage forms with innovative delivery mechanisms, which exceeds
those developed by pharmaceutical companies,” says Frank Santillo, Ph.D., Bilcare
Research’ senior director for research services. “Most importantly, we have the
expertise to take a drug candidate from concept to clinical production without
the client suffering critical and costly delays as a result of hand-offs,
continues Frank”
About Bilcare Global Clinical Supplies
Bilcare Global Clinical Supplies serves the Americas, Europe,
and Asia with clinical trial materials support, services, and complete project
management. Its services for solid, semi-solid, liquid, DEA (CI-V), and biotech
clinical trial materials (CTM) satisfy a broad range of requirements; from
pre-formulation research and development, manufacturing, analytical services
and clinical supplies clinical packaging and labeling, to IVRS, QP services,
controlled temperature (cold chain) CTM storage, worldwide distribution, and
returns and destructions accountability.

No comments:
Post a Comment